Cladribine Shows a Robust Safety Profile – Both as First-Line and Subsequent Therapy in MS
There is limited knowledge regarding the specific effects of cladribine on the immune system in patients with multiple sclerosis (MS). Cladribine, a purine analogue and immunomodulatory agent whose active metabolite accumulates intracellularly, inhibits DNA synthesis and induces apoptosis, predominantly in lymphocytes. New data presented at ECTRIMS 2025 demonstrate that cladribine exhibits a robust safety profile, both as a first-line treatment and as a subsequent therapy in MS.
